 |
|
Intrathecal Interferon as Treatment of Multiple SclerosisA Planned Multicenter Study
Lawrence Jacobs, MD;
Judith A. O'Malley, PhD;
Arnold Freeman, MD;
Peter Reese, JD
Arch Neurol. 1983;40(11):683-686.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Previous research indicates that multiple sclerosis (MS) may be caused, at least in part, by a viral infection of the CNS.1,2 Interferon is a naturally occurring biologic product that has potent antiviral activities.3-17 It has been demonstrated (in animals and humans) that only a fraction of the total dose crosses the blood-brain barrier when interferon is administered systemically, but the substance can safely be administered intrathecally (IT).6,12,18-23 For these reasons, we conducted a preliminary randomized study assessing the effects of IT administered human-fibroblast interferon (interferon-β) in a small series of patients with MS. That study demonstrated a beneficial effect.24,25 A larger, multicenter, definitive study of the efficacy of IT administered interferon-β is now under design. The participating centers are the Dent Neurologic Institute (DNI), Buffalo, the Roswell Park Memorial Institute (RPMI), Buffalo, the University of Rochester (New York) Medical Center (URMC), and the Walter Reed Army
. . . [Full Text PDF of this Article]
Author Affiliations
From the Dent Neurologic Institute and the Division of Neurobiology, Department of Physiology, State University of New York (Dr Jacobs) and Roswell Park Memorial Institute (Drs O'Malley and Freeman and Mr Reese), Buffalo.
Footnotes
Reprint requests to Dent Neurologic Institute, 3 Gates Circle, Buffalo, NY 14209 (Dr Jacobs).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
